Close Menu

Quidel

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all swung up on positive coronavirus vaccine news.

An analysis suggests rapid SARS-CoV-2 tests may have drawbacks under real-world conditions, the New York Times reports.

Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.

The firm reported $57.8 million in revenues for its Lyra SARS-CoV-2 molecular diagnostic assays in the quarter.

Nevada's About Face

The New York Times reports Nevada has reversed a statewide order directing nursing homes to halt their use of two rapid coronavirus tests.

Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all rose in August.

While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.

Pages

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.